Trial Profile
An Open-Label, Phase 2, Pilot Study Investigating the Safety, Clinical Activity, Pharmacokinetics, and Pharmacodynamics of Oral Treatment With the BTK Inhibitor PRN1008 in Patients With Newly Diagnosed or Relapsing Pemphigus Vulgaris
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 15 Feb 2023
Price :
$35
*
At a glance
- Drugs Rilzabrutinib (Primary) ; Prednisone; Rituximab
- Indications Pemphigus vulgaris
- Focus Adverse reactions; Proof of concept; Therapeutic Use
- Acronyms Believe-PV
- Sponsors Principia Biopharma
- 03 May 2021 Results (n=27) assessing efficacy and safety of oral rilzabrutinib in patients with pemphigus vulgaris, published in the British Journal of Dermatology.
- 12 Jun 2020 Results published in the Principia Biopharma Media Release.
- 12 Jun 2020 According to a Principia Biopharma media release, positive data from the Part B of the study was presented as part of the virtual Late-Breaker session of the American Academy of Dermatology.